What's new?

Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts
TGCT Support is a global organization. Aligned with our mission, we have expanded our reach by assisting a French community of patients become established as an association. We are inspired by these patients and hope to continue to work together to bring resources to patients globally!
Check out all the CTOS 2022 Posters for TGCT
Expert Q&A Webinar Live, here!
Picture
                     TGCT Support Announces its summer webinars! View our TGCT                             Expert Q&A flyer here and our Surgery and Pain Management                               flyer here
Picture
TGCT Support supports patients with video for Rare Disease Day

Watch here 
Picture
First Western US to open Phase 3 for Vimseltinib 

​Check it out here
Picture
Director of Giant Cell Tumor Programs at TGCT Support, Sydney Stern, gives an overview of TGCT for CheckRare

​                       Check it out!
Picture
AmMax Bio announces positive results during AMB-05X Phase 2 trial of local injections to the knee

                           Learn more here
DCC-3014 (Vimseltinib) launches its Phase 3 Trial

Learn more here
TGCT Support Launches Support Groups!

Check it out here
​
Picture
National Organization for Rare Diseases (NORD) updates their TGCT page
​
Check it out here
AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of AMB-05X for Tenosynovial Giant Cell Tumor (TGCT)

Read more here
CancerCare® Publishes White Paper Highlighting Gaps in Education and Care for Patients with Tenosynovial Giant Cell Tumors (TGCT)

Read more here
DCC-3014 (vimseltinib) shows promise as a new selective treatment for TGCT

Read more here
New Clinical Trial from AmMax Bio for an intra-articular joint injection for TGCT patients

Read more here

TGCT SUPPORT IS A PROGRAM OF THE LIFE RAFT GROUP

Picture
155 US Highway 46, Suite 202                      Wayne, NJ 07470                      support@tgctsupport.org